the REMONO-CD and the REMONO-UC Studies (REMONO)
Non-inferiority REal-world Evidence Study Comparing the Effectiveness of Subcutaneous Infliximab MONOtherapy and Subcutaneous Infliximab Combined With Immunosuppressive Therapy in Patients With Crohn's Disease and Ulcerative Colitis.
Infliximab was the first-in-class anti-TNF agent approved for treating patients with IBD, both for Crohn's disease (CD)1 and ulcerative colitis (UC)2. Infliximab is administered by intravenous infusions and demonstrated its superiority over placebo to induce and maintain steroid-free clinical remission. Besides, SONIC and SUCCESS trials showed that combination therapy (infliximab + immunosuppressant) was more effective than infliximab alone to induce clinical remission3,4. Moreover, the PANTS cohort confirmed the benefits of combination therapy to induce remission and to prevent immunogenicity over time5. Accordingly, current guidelines recommend to use infliximab in combination with an immunosuppressive therapy. Recently, subcutaneous (SC) infliximab has been developed and is now approved for patients with CD and UC6. The LIBERTY-CD and LIBERTY-UC trials showed that SC infliximab is more effective than placebo to maintain clinical remission7. Real-world evidence studies, such as the REMSWITCH program8,9, reported that switching from IV to SC infliximab is feasible, safe and well accepted leading to a low risk of relapse including in patients with intensified IV doses. In addition to its better acceptability compared to IV regimen, SC infliximab seems to have a better pharmacokinetic profile that can lead to reduced risk of immunogenicity and thus question the need for using combination therapy with SC infliximab6-9. No data enables to draw any firm conclusion on this topic10.
In the REMONO studies (REMONO-UC and REMONO-CD), we aim to show the non-inferiority of SC infliximab monotherapy to maintain steroid-free clinical remission compared to combination therapy in patients with CD and UC.
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
It will be a retrospective multicentre study (22 centres). Data will be collected from the electronic medical records and pseudonymized from routine clinical care between 01/01/2023 and 01/07/2025. Data will be entered the electronic CRF (RedCAP).
The main data collected at the different time points : age, disease duration, smoking status, prior bowel resection, Montreal classification (location, behaviour, extent), perianal lesions, upper GI involvement, previous IBD medications, concomitant IBD medications (including doses and intervals), disease activity (stool frequency, abdominal pain, bowel urgency, CRP level, faecal calprotectin level, endoscopic activity, MRI scores, IUS lesions), side effects, pharmacokinetics (infliximab serum level, anti-infliximab antibodies).
Undersøgelsestype
Tilmelding (Anslået)
Kontakter og lokationer
Studiesteder
-
-
-
Amiens, Frankrig
- CHU Amiens
-
Besançon, Frankrig
- CHU Besançon
-
Clermont-Ferrand, Frankrig, 63000
- Chu Clermont Ferrand
-
Clichy, Frankrig
- Hôpital Beaujon AP-HP
-
Créteil, Frankrig
- Hôpital Henri-Mondor AP-HP
-
Dijon, Frankrig
- CHU Dijon
-
Grenoble, Frankrig
- CHU Grenoble
-
Le Kremlin-Bicêtre, Frankrig
- Hôpital Bicêtre AP-HP
-
Lille, Frankrig
- Chu Lille
-
Lyon, Frankrig
- Hospice Civil de Lyon
-
Marseille, Frankrig
- Hôpital Henri-Mondor AP-HP
-
Montpellier, Frankrig
- CHU Monptellier
-
Nancy, Frankrig
- CHU Nancy
-
Nantes, Frankrig
- CHU Nantes
-
Neuilly-sur-Seine, Frankrig
- Institut des MICI
-
Nîmes, Frankrig
- CHU Nimes
-
Rouen, Frankrig
- CHU Rouen
-
Toulouse, Frankrig
- CHU Toulouse
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- Patients with UC (REMONO-UC) or with CD (REMONO-CD) ≥ 18 years
- Who received at least one SC injection of infliximab after IV induction (5 mg/kg at week 0, week 2 ± week 6)
- Infliximab started for symptomatic CD (PRO2: abdominal pain > 1 or stool frequency >3) or UC (partial Mayo score >2)
- Follow-up of at least 3 months (except for those who failed or were intolerant to SC infliximab before 3 months)
Exclusion Criteria:
- Unclassified colitis
- Infliximab started for isolated perianal CD, to prevent CD endoscopic postoperative recurrence or for acute severe colitis
- Permanent stoma
- Total colectomy with IPAA
- Concomitant other biological therapy or small molecule
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
|---|
|
REMONO CD
Patients with crohn disease
|
|
REMONO UC
Patient with ulcerative colitis
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Steroid-free clinical remission in REMONO CD
Tidsramme: From 3 months up to 1 year after the start of treatment
|
Steroid-free clinical remission (defined using PRO-2 as normal stool frequency ≤ 3 bowel movement a day and no moderate or severe abdominal pain (CDAI subscore ≥ 2)) Results will be expressed as the percentage of months (4-weeks period) spent in steroid-free clinical remission.
(The statistical unit being the month and not the patient).
|
From 3 months up to 1 year after the start of treatment
|
|
Steroid-free clinical remission in REMONO UC
Tidsramme: From 3 months up to 1 year after the start of treatment
|
Steroid-free symptomatic remission (defined using PRO-2 as normal stool frequency and no rectal bleeding) Results will be expressed as the percentage of months (4-weeks period) spent in steroid-free clinical remission.
(The statistical unit being the month and not the patient).
|
From 3 months up to 1 year after the start of treatment
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Anthony BUISSON, CHU de Clermont-Ferrand
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 2025 BUISSON_CF525
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Crohns sygdom (CD)
-
L2 Bio, LLCFDAMap; Akan Biosciences, Inc.Ikke rekrutterer endnuCrohn & amp;#39; s | Crohn & amp;#39; s sygdom (CD)
-
Vanderbilt University Medical CenterTakeda Pharmaceuticals U.S.A., Inc.Aktiv, ikke rekrutterendeInflammatorisk tarmsygdom (IBD) | Colitis ulcerosa (UC) | Crohn & amp;#39; s sygdom (CD)Forenede Stater
-
Groupe d'Etude Therapeutique des Affections Inflammatoires...AbbVie; Gilead Sciences; Roche Pharma AG; Takeda; Celgene; BiogenAktiv, ikke rekrutterende
-
Azienda Ospedaliera Ordine Mauriziano di TorinoAfsluttet
-
Mashhad University of Medical SciencesAfsluttetInteraktiv CD-baseret uddannelse
-
University of MichiganThe Leona M. and Harry B. Helmsley Charitable TrustRekrutteringInaktiv Crohns sygdom (CD)Forenede Stater
-
Anterogen Co., Ltd.Afsluttet
-
Groupe Hospitalier Paris Saint JosephAfsluttet
-
Shandong UniversityAktiv, ikke rekrutterende
-
The Cleveland ClinicMesoblast, Inc.AfsluttetCrohn colitisForenede Stater